
News|Articles|February 13, 2019
Xospata for Relapsed or Refractory AML
Author(s)Drew Boxler
Advertisement
Xospata (gilteritinib, Astellas)
Indications: Adult patients with relapsed or refractor acute myeloid leukemia (AML) with an FLT3 mutation.
Dosage: 120 mg orally once-daily; 40 mg tablets
Contraindications: Hypersensitivity to gilteritinib or any of the excipients. Naphylactic reactions have been observed in clinical trials.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
How Pharmacists Take Control of Medical Billing
2
Data Show Rise in GLP-1 Poison Center Calls Tied to Dosing Errors
3
Lowered Pneumococcal Vaccination Age Has Yet to Close Awareness Gap
4
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
5






























